<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: To analyze the clinical characteristics of B-cell non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL) patients and the therapeutic efficacy of French-American-British <z:hpo ids='HP_0002665'>Lymphoma</z:hpo> Malins de Burkitt 96 and the recent United Kingdom Children's <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Study Group B-cell NHL guidelines in the tertiary care hospital of a developing country </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Patients aged &lt; or =18 years registered at our hospital between January 1995 and December 2006 with histologically proved B-Cell NHL were selected for retrospective analysis </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: Of the total of 131 patients registered, 122 patients were eligible for evaluation </plain></SENT>
<SENT sid="3" pm="."><plain>Of these 95 had Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, 22 diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and five had B-cell NHL not otherwise specified </plain></SENT>
<SENT sid="4" pm="."><plain>The mean age was 8.4 years </plain></SENT>
<SENT sid="5" pm="."><plain>Overall 42 children had a baseline weight less than the 10th centile </plain></SENT>
<SENT sid="6" pm="."><plain>A total of 37 had <z:chebi fb="3" ids="27226">uric acid</z:chebi> &gt;10 mg/dl and 55 had a <z:chebi fb="4" ids="24996">lactate</z:chebi> dehydrogenase level &gt;500; 73 had stage III and 31 had stage IV while only four presented at stage I and 14 at stage II </plain></SENT>
<SENT sid="7" pm="."><plain>The abdomen was the commonest site of disease </plain></SENT>
<SENT sid="8" pm="."><plain>A total of 45 patients died; 28 due to <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e>, nine due to <z:e sem="disease" ids="C0041364" disease_type="Disease or Syndrome" abbrv="">tumor lysis syndrome</z:e> and six of uncontrolled disease </plain></SENT>
<SENT sid="9" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> <z:hpo ids='HP_0011420'>deaths</z:hpo> occurred within an average of 35 days from starting treatment </plain></SENT>
<SENT sid="10" pm="."><plain>Our 5-year overall survival rate was 68 percent and our event-free survival was 55 percent </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSION: Late presentation with advanced disease, poor nutritional status and high risk of exposure to infective agents <z:hpo ids='HP_0000001'>all</z:hpo> contribute to the high mortality in patients treated with intensive protocols in resource-poor countries </plain></SENT>
</text></document>